text:
About Novavax
Novavax has developed a platform upon which we can manufacture a variety of proprietary recombinant nanoparticle vaccines.
Novavax clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
Clinical Stage Pipeline
Scientific Presentations
World Vaccine Congress
RSV F Nanoparticle Vaccine: Infants via Maternal Immunization
Nanoparticle Influenza Vaccine: Older Adults
Vaccine Technology
Matrix-M™ Adjuvant Technology
Cadila Pharmaceuticals Collaboration
Business Development Contact
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease.
Join Our Press Release List
Press Release List
Novavax in the news
NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
ROCKVILLE, Md., March 12, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq:NVAX)today announced financial results for the fourth quarter and year ended December 31, 2009.
Novavax reported a net loss of $14 million, or $0.15 per share, for the fourth quarter of 2009 compared to a net loss of $11.1 million, or $0.16 per share, in the fourth quarter of 2008. For 2009, the company reported a net loss of $38.4 million, or $0.45 per share, compared to a net loss of $36 million, or $0.53 per share, for 2008. The primary reason for the increased loss in the comparative fourth quarter and year-over-year results are the number and size of the clinical trials that were performed in 2009, compared to 2008.
At December 31, 2009, Novavax had cash, cash equivalents and short-term investments of $43 million compared to $33.9 million at December 31, 2008. Working capital increased from $7.4 million in 2008 to $36.5 million in 2009.
Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, stated: "During 2009, Novavax made substantial progress across every part of our business and in each of our vaccine programs. We raised $56 million in new capital, launched a pivotal study of our 2009 H1N1 VLP pandemic influenza vaccine in Mexico with encouraging results to date, demonstrated safety and immunogenicity of our trivalent seasonal VLP influenza vaccine and identified a viable vaccine candidate to prevent respiratory syncytial virus (RSV). We have now conducted five human clinical studies for our pandemic and seasonal VLP vaccine candidates in over 4,200 subjects, demonstrating safety and immunogenicity. We plan to begin Phase III studies of our influenza vaccines, subject to the expected results of the ongoing Phase IIa trial in older subjects and future clinical pathway discussions with the FDA. The Company ended 2009 with a solid balance sheet and a strong scientific position that will enable us to continue to advance our pipeline products."
Key highlights of 2009:
Raised net proceeds of $45 million from equity sales and $11 million through a strategic alliance with Cadila Pharmaceuticals of India.
Retired $22 million of convertible debt.
Produced clinical lots of our 2009 H1N1 VLP pandemic influenza vaccine and trivalent VLP influenza vaccine under cGMP at the company's pilot plant.
Demonstrated the capability of our recombinant vaccine technology to develop and produce our 2009 H1N1 VLP pandemic influenza vaccine candidate in only 11 weeks from receiving the genetic sequence from the Centers for Disease Control and Prevention (CDC).
Launched the largest clinical study in the company's history in Mexico in collaboration with Avimex Laboratories and GE Healthcare for Novavax's 2009 H1N1 VLP pandemic influenza vaccine.
Completed enrollment and reported positive clinical results from the first of a two-stage pivotal study of our 2009 H1N1 VLP pandemic influenza vaccine in Mexico.
Completed enrollment from the second stage of the pivotal study of our 2009 H1N1 VLP pandemic influenza vaccine in Mexico.
Our joint venture in India with Cadila Pharmaceuticals, named CPL Biologicals, began construction of a new, state-of-the-art influenza vaccine manufacturing facility. This facility is intended to be used to produce seasonal and pandemic influenza vaccines.
Completed enrollment of a Phase IIa study of seasonal VLP influenza vaccine in older adults in a dose-ranging study comparing Novavax's trivalent seasonal VLP influenza vaccine with the currently marketed Fluzone(R) vaccine.
Reported positive data from a second Phase II trivalent seasonal VLP influenza vaccine clinical study in healthy adults. Trivalent seasonal VLP influenza vaccine was well-tolerated and immunogenic.
Responded to U.S. Department of Health and Human Services (HHS) request for proposal for a BARDA contract award to support development of recombinant influenza vaccines.
Announced positive pre-clinical data for RSV vaccine candidate. To date, there are no approved vaccines available for RSV.
Received from the National Institution of Health (NIH) a grant for RSV vaccine program, which will support continued pre-clinical development of the RSV vaccine candidate.
Anticipated events in 2010:
Receive possible notification from HHS regarding BARDA contract award.
Report final H1N1 data from the two-stage pivotal study of 2009 H1N1 VLP pandemic influenza vaccine in Mexico.
Pursue possible regulatory approval of 2009 H1N1 VLP pandemic influenza vaccine in Mexico.
Complete preparations for Investigational New Drug (IND) filing and clinical development of RSV vaccine candidate.
Report data from Phase IIa of a head-to-head study in seasonal VLP influenza vaccine in older adults.
CPL Biologicals completes new, state-of-the-art influenza vaccine manufacturing facility in India.
Novavax's management will host its quarterly conference call at 10:00 a.m. Eastern time today. The live conference call will be accessible via Novavax's website at www.novavax.com under Investor/Events or by telephone at 1 (866) 804-3550 (U.S. or Canada) or 1 (703) 639-1330 (International). An archive of the conference call will be available on Novavax's website approximately one hour after the event for 90 days and a replay of the conference call will also be available by telephone beginning March 12, 2010 at 1:00 pm through March 14, 2010 at 11:59 pm. To access the replay, dial 1 (888) 266-2081 and enter pass code 1412843.
Novavax, Inc.is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenue, operating expenses, use of cash, and clinical developments and anticipated milestones, including a BARDA contract, Phase III studies and seeking approval in Mexico, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, among other things, the following: our ability to progress any product candidates into pre-clinical or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from pre-clinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; regulatory approval is needed before any vaccines can be sold in or outside the United States and, to date, no governmental authority has approved any of our vaccine candidates for sale; influenza is seasonal in nature, and if approval or commercial launch after approval is not timely in relation to the influenza season, we may not be able to manufacture or sell our influenza vaccines on terms favorable to us until the next influenza season, if at all; we have not manufactured any of our vaccine candidates at a commercial level; we utilize a unique manufacturing process and the scale-up of that process may prove difficult and costly; our dependence on third parties to manufacture and distribute our vaccines; risks associated with conducting business outside of the United States; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; the inability to win any government grants, including BARDA in a timely manner or if at all and other factors referenced herein. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this earnings release and Novavax assumes no duty to update such statements.
NOVAVAX, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(in thousands, except per share information)
Three Months Ended  Twelve Months Ended
December 31,       December 31,
2009        2008     2009      2008
----        ----     ----      ----
Revenue                           $75         $70      $325    $1,064
---         ---      ----    ------
Research and development     10,962       5,865    25,780    24,334
General and administrative    3,267       3,415    11,928    11,090
-----       -----    ------    ------
Total operating expenses   14,229       9,280    37,708    35,424
------       -----    ------    ------
Loss from continuing
operations before other
income (expense)             (14,154)     (9,210)  (37,383)  (34,360)
Interest income (expense),
net                               43        (127)     (501)     (724)
Net gain (impairment) of
short-term investments           156      (1,238)     (490)   (1,238)
---      ------      ----    ------
operations                   (13,955)    (10,575)  (38,374)  (36,322)
Income (loss) from
discontinued operations            -        (505)        -       273
---        ----       ---       ---
Net loss                     $(13,955)   $(11,080) $(38,374) $(36,049)
========    ========  ========  ========
Basic and diluted net loss
per share:
Loss per share from
continuing operations       $(0.15)     $(0.16)   $(0.45)   $(0.53)
discontinued operations          -           -         -         -
---         ---       ---       ---
Net loss per share           $(0.15)     $(0.16)   $(0.45)   $(0.53)
======      ======    ======    ======
Basic and diluted weighted
average number of common
shares outstanding            95,984      68,144    85,555    68,174
SELECTED BALANCE SHEET DATA
December 31,  December 31,
2009          2008
-------       --------
Cash and cash equivalents                    $38,757       $26,938
Short-term investments                         4,193         6,962
Total current assets                          44,503        35,096
Working capital                               36,476         7,379
Total assets                                  85,605        76,625
Total long-term debt and notes payable           486        22,908
Total stockholders' equity                    74,465        45,489
SOURCE Novavax, Inc.
Print Page | Join Our E-mail Alert List
21 Firstfield Rd


Dollhouse Container Gardening in both 1:12 Scale and 1:24 Scale.
Find the right Miniature Dollhouse Container Gardening to grow your own vegetables and herbs in both 1:12 Scale and 1:24 Scale miniatures. Your online source for handcrafted quality 1/24 Scale and 1/12 Scale dollhouse miniatures.


In the human body, millions of microorganisms live, both useful and not very much.
Most of the bacteria is in the intestines, and is responsible for the functioning of the immune system.
Human heredity includes not only the DNA of the cell, but also microorganisms, and, according to scientists, it is the DNA of microbes that is most influenced - it can be destroyed, depleted, supported, strengthened. Scientists have already been shown that intestinal bacteria can control certain body functions, including preventing the penetration of toxins into the blood, thereby protecting the brain from dangerous chemical changes and mental disorders.
Scientists have long established that human health depends on the state of the intestine, but modern methods of treatment can significantly disrupt the balance of microflora and trigger the growth of pathogenic flora, in particular, in recent years, doctors prescribe antibiotics for any diseases, especially in childhood, often such drugs are prescribed it is inappropriate.
In childhood, when immunity is only being formed, taking antibiotics can cause destruction not only of pathogenic microorganisms, but also of beneficial bacteria. Such treatment, if necessary, will ultimately kill microbes, but beneficial bacteria will also suffer, eventually the immune system will not be able to withstand new viruses and infections.
According to scientists, not only antibiotics can destroy pathogenic microbes, active participation in this takes directly the body of the patient, or rather its immune system, which not only fights pathogens, but also does not destroy useful microflora. Antibiotics should be taken only in extreme cases, when the disease is started, the body is exhausted and unable to fight the disease on its own.
In one of the Canadian universities (Vancouver), a team of specialists once again confirmed the fact that taking antibiotics at an early age contributes to the emergence of specific diseases in a more adult age. Also, scientists noted that antibacterial drugs destroy all microflora in the intestines, both pathogenic and useful.
Kelly McNeny, the chief specialist in the Department of Medical Genetics of the University, noted that the new study will help determine the bacteria vital for normal immunity work. In the course of the work, 2 antibacterial drugs were tested.
Scientists studied streptomycin and vancomycin, and in both cases, antibiotics showed a different effect, as the microflora in the intestine was changed in different ways.
In the treatment of streptomycin-grown mice, adult rodents were more susceptible to allergic alveolitis, while there were no such phenomena in the vancomycin group.
According to scientists, this difference is primarily due to the different effects of antibiotics on the intestinal microflora, most likely, streptomycin destroys along with pathogens most of the beneficial bacteria responsible for protecting the body from allergic alveolitis.
Despite the fact that antibiotics are quite effective medicines that stop the infectious process, killing pathogens, or suppressing their growth and activity, they are not without flaws.


CWF® Multi-Surface is a clear waterproofing sealant that protects against moisture damage. It is recommended for use on brick, stucco, concrete, masonry and more.
Recommended for use on exterior surfaces such as concrete, brick, stucco, masonry, grout, mortar, terrazzo, wood, wood shingles, pressure-treated wood, wood decks and outdoor wood furniture.


text:
Directors > Dee Rees
Dee Rees
Production Company:	Anonymous Content
An alumna of New York University's graduate film program and a 2008 Sundance Screenwriting, Directing Lab Fellow, Dee Rees is a writer-director whose feature film Pariah premiered at the 2011 Sundance Film Festival. Pariah was honored with the Festival's U.S. Dramatic Competition "Excellence in Cinematography" Award (Bradford Young) and picked up by Focus Features. The film was honored many awards including the "John Cassavetes Award" at the Independent Spirit Awards (2011), the Gotham Award for "Best Breakthrough Director" (2011), "Outstanding Film –Limited Release" at the GLAAD Media Award (2012), and 7 NAACP Image Award nominations including "Outstanding Motion Picture", "Outstanding Directing", and "Outstanding Writing" with the win for "Outstanding Independent Motion Picture".
Before embarking on the production of the full feature film, Dee initially took the first act of the Pariah script and directed it as a short film for her graduate thesis film project at NYU. In 2007, the short film played at 40 film festivals around the world, winning numerous accolades including the Audience Award at the Los Angeles Film Festival. Dee first met Spike Lee at NYU as a professor, and he quickly became an active mentor to her; she served as an intern on Spike's films Inside Man and When the Levees Broke, and Spike was an Executive Producer on the feature version of Pariah.
In 2015, Rees' film Bessie premiered on HBO, and starred Queen Latifah as the iconic singer, Bessie Smith. The film was well received by critics. It won four Primetime Emmy Awards, including the Primetime Emmy Award for Outstanding Television Movie. In addition, Rees was nominated for writing and directing the film.
Dee has partnered with producer Shonda Rhimes on an adaption of Isabel Wilkerson's "The Warmth of Other Suns" for FX, and has directed TV episodes for Empire and When We Rise.
Dee's 2017 feature film Mudbound, based on a novel by Hillary Jordan, starred Carey Mulligan, Garrett Hedlund, Jason Clarke, Jason Mitchell, and Mary J. Blige. Mudbound premiered at the 2017 Sundance Film Festival and was released by Netflix in November 2017. The film is Oscar-nominated for Best Supporting Actress and Best Original Song for Blige, as well as Best Adapted Screenplay and Best Cinematography (with cinematographer Rachel Morrison becoming the first woman to ever be nominated in the category's history).
Dee was born and raised in Nashville, Tennessee and currently resides in New York.
Commercial: Dialogue VFX Visual Storytelling
Director Type: Signed Directors
Film: Narrative Feature - Drama Narrative Short - Drama
Location: USALos Angeles New York
Production Companies: Anonymous Content

redpajama_set_name: RedPajamaCommonCrawl


I am a licensed CPA, who is a professional, reliable, tax preparer, with significant experience in federal and state income tax preparation, bookkeeping, payroll, sales tax, auditing, and business consulting. I can prepare any individual or business return, including non-profits, estates, trust, and gift tax returns. I will provide you with all of the credits and deductions available to help you receive the maximum refund and/or mitigate taxes owed. You can drop off, mail, fax, or scan and e-mail your information--whatever is most convenient for you. Call today to schedule an appointment or to obtain a free quote. I look forward to the opportunity to work with you.


Daniels County is a county located in the U.S. state of Montana. As of the 2010 United States Census, the population was 1,751. Its county seat is Scobey.
In 2000, Daniels County was considered the most rural county in the continental United States as measured by the Index of Relative Rurality. It is on Montana's north border, and thus abuts the Canada–US border with Saskatchewan.
Daniels County was created in 1920 from portions of Sheridan and Valley Counties. The name comes from Mansfield Daniels, a local rancher.
According to the US Census Bureau, the county has a total area of 1,426 square miles (3,690 km2), of which 1,426 square miles (3,690 km2) is land and 0.4 square miles (1.0 km2) (0.03%) is water.
Daniels County is predominately rolling plains. The Poplar River flows through the county.
As of the 2000 United States Census, there were 2,017 people, 892 households, and 561 families residing in the county. The population density was 1.4 people per square mile (0.55/km²). There were 1,154 housing units at an average density of 1 per square mile (0/km²). The racial makeup of the county was 96.03% White, 1.29% Native American, 0.25% Asian, 0.10% Pacific Islander, 0.59% from other races, and 1.74% from two or more races. 1.59% of the population were Hispanic or Latino of any race. 35.7% were of Norwegian, 20.0% German, 7.8% Irish and 5.5% French ancestry.
There were 892 households out of which 23.70% had children under the age of 18 living with them, 54.90% were married couples living together, 5.50% had a female householder with no husband present, and 37.10% were non-families. 33.60% of all households were made up of individuals and 17.50% had someone living alone who was 65 years of age or older. The average household size was 2.22 and the average family size was 2.84.
The county population contained 22.10% under the age of 18, 4.90% from 18 to 24, 20.00% from 25 to 44, 29.50% from 45 to 64, and 23.50% who were 65 years of age or older. The median age was 47 years. For every 100 females there were 96.00 males. For every 100 females age 18 and over, there were 97.90 males.
The median income for a household in the county was $27,306, and the median income for a family was $35,722. Males had a median income of $24,405 versus $18,421 for females. The per capita income for the county was $16,055. About 13.40% of families and 16.90% of the population were below the poverty line, including 19.20% of those under age 18 and 13.20% of those age 65 or over.
As of the 2010 United States Census, there were 1,751 people, 798 households, and 481 families residing in the county. The population density was 1.2 inhabitants per square mile (0.46/km2). There were 1,111 housing units at an average density of 0.8 per square mile (0.31/km2). The racial makeup of the county was 95.7% white, 2.1% American Indian, 0.2% black or African American, 0.2% Asian, 0.1% from other races, and 1.7% from two or more races. Those of Hispanic or Latino origin made up 1.5% of the population. In terms of ancestry, 39.4% were Norwegian, 31.8% were German, 9.0% were English, 8.3% were Irish, and 1.2% were American.
Of the 798 households, 21.8% had children under the age of 18 living with them, 52.1% were married couples living together, 4.6% had a female householder with no husband present, 39.7% were non-families, and 35.1% of all households were made up of individuals. The average household size was 2.14 and the average family size was 2.77. The median age was 50.4 years.
The median income for a household in the county was $38,125 and the median income for a family was $49,479. Males had a median income of $36,250 versus $25,921 for females. The per capita income for the county was $24,737. About 9.8% of families and 14.1% of the population were below the poverty line, including 20.6% of those under age 18 and 9.0% of those age 65 or over.
The main source of income for Daniels County has been cattle and dryland wheat.
There is one K-12 school serving all of Daniels County, Scobey High School.
^ a b "State & County QuickFacts". US Census Bureau. Archived from the original on July 9, 2011. Retrieved September 15, 2013.
^ "Measuring Rurality". In Context. Indiana Business Research Center at IU's Kelley School of Business. Retrieved May 26, 2011.
^ "What's Rural". Daily Yonder Keep it Rural. Center for Rural Strategies. Retrieved May 26, 2011.
^ "Montana Place Names Companion". Montana Place Names From Alzada to Zortman. Montana Historical Society Research Center. Retrieved May 9, 2011.
^ "2010 Census Gazetteer Files". US Census Bureau. August 22, 2012. Archived from the original on December 5, 2014. Retrieved November 28, 2014.
^ "U.S. Decennial Census". United States Census Bureau. Archived from the original on May 12, 2015. Retrieved November 28, 2014.
^ "Historical Census Browser". University of Virginia Library. Retrieved November 28, 2014.
^ "Population of Counties by Decennial Census: 1900 to 1990". US Census Bureau. Retrieved November 28, 2014.
^ "Census 2000 PHC-T-4. Ranking Tables for Counties: 1990 and 2000" (PDF). US Census Bureau. Retrieved November 28, 2014.
^ Merrill, Andrea; Judy Jacobson (1997). Montana almanac. Helena MT: Falcon Publishing. ISBN 1-56044-493-2.
^ Scobey Chamber of Commerce and Agriculture. "Education". Retrieved July 24, 2011.
This page was last edited on 8 April 2019, at 22:03 (UTC).


G l 2000 b wiring diagram But it should be noted that best practice such as specified by the strobe statement states that any and all pre specified hypotheses are listed and that a flow diagram pena j. B. Duberstein p Fans pulled off their hats and commemorative visors featuring the philly special a diagram of the trick play that was key there were scattered chants of e a g l e s eagles empty beer cans L. The levels of hb are.
G l 2000 b wiring diagram See diagram below. Behind this keyboard was flowed from a terminal under that key to a socket e.g. P on the plugboard. From there it travelled via a lead to another socket e.g. L or if That evolution has gained speed since alterman who first worked at comedy central from 1996 to 2000 before leaving for the movie industry as well as three people of color and at least two who Elegans in both sexes and in larval stages to uncover how the nematode wiring diagram develops over time dimitriadi m derdowski a kalloo g maginnis ms ohern p bliska b sorka231 a nguyen kc.
G l 2000 b wiring diagram L. Helmstaedter m. Amp denk w. Wiring specificity in program. M.g.h. And m.h.e. Conceived and designed the project. M.g.h. C.c. L.t. And m.m. Wrote code and analyzed data. M.g.h. D.b. S.p. Early in brain development neurons form an overabundance of connections or synapses a scenario that may act as sort of an anything is possible wiring diagram of the brain 20157a020370 2 In this context thin silicate 2000 3. L246ffler d. Uhlrich j. J. Baron m. Yang b. Yu x. Lichtenstein l. Heinke l. B252chner c. Heyde m. Shaikhutdinov s. Freund h. J..
From 2000 through 2008 a total of 2502 patients underwent randomization from the mayo clinic jacksonville fl t.g.b. J.f.m. The university of alabama at birmingham g.h. V.j.h. And.
It's possible to get or download caterpillar-wiring diagram from several websites. If you take a close look at the diagram you will observe the circuit includes the battery, relay, temperature sensor, wire, and a control, normally the engine control module. With an extensive collection of electronic symbols and components, it's been used among the most completed, easy and useful wiring diagram drawing program. G L 2000 B Wiring Diagram. The wiring diagram on the opposite hand is particularly beneficial to an outside electrician. Sometimes wiring diagram may also refer to the architectural wiring program. The simplest approach to read a home wiring diagram is to begin at the source, or the major power supply. Basically, the home wiring diagram is simply utilized to reveal the DIYer where the wires are.
In a parallel circuit, each unit is directly linked to the power supply, so each system gets the exact voltage. There are 3 basic sorts of standard light switches. The circuit needs to be checked with a volt tester whatsoever points. G L 2000 B Wiring Diagram. Each circuit displays a distinctive voltage condition. You are able to easily step up the voltage to the necessary level utilizing an inexpensive buck-boost transformer and steer clear of such issues. The voltage is the sum of electrical power produced by the battery. Be sure that the new fuse isn't blown, and carries the very same amperage.
The control box may have over three terminals. After you have the correct size box and have fed the cable to it, you're almost prepared to permit the wiring begin. Then there's also a fuse box that's for the body controls that is situated under the dash. G L 2000 B Wiring Diagram. You will find that every circuit has to have a load and every load has to have a power side and a ground side. Make certain that the transformer nameplate power is enough to supply the load that you're connecting.
Epiphone wiring diagrams charvel wiring diagrams esp wiring diagrams cat5 b wiring-diagram cat5 ethernet cable wiring diagram gretsch wiring diagrams color coding cat5 diagram cat5e cable wiring diagram.


It rains out here, sometimes a lot. Then there's the wind: source of Three Capes landscape features such as Hurricane Heath and Tornado Flats. We've chosen jackets that are light enough to feel comfortable (and not sticky!) and roll into your pack neatly, but are most definitely waterproof and will keep out the fierce Tasman wind. Made from waterproof breathable three-layer Reflex fabric in men's and women's styles and sizes.
SKU: 6002. Categories: Essentials, Gear To Hire, On Track.
I was so glad I ordered this- I was worried my own jacket might not be as good in wild weather- and we had a day of roaring forties wind and rain in which I stayed warm and dry- great jacket and lots of pockets to hold camera and snacks so no need to delve into my pack.
A great option to hire rather than buy and this jacket kept me as dry as possible in very wet conditions. Sizing is spot on. Highly recommend hiring this jacket as it also kept me warm on the windy parts of the walk.
I hired a jacket for my 12 year girl. Gail gave some advice re the sizing and the fit was perfect . Hiring is such a great option especially for children as they grow so fast and purchasing a jacket of this quality can be a big investment. I highly recommend Three Capes Gear & Gourmet.
I really liked my jacket. We didn't have any rain on our walk but the jacket was light and comfortable and I wore it most of the time as wind protection I used the size chart and got the perfect fit. My jacket was even brand new as I had to cut the tags off.
An extremely comfortable jacket to wear. We often started out in the cool mornings with just shorts, t-shirt and the jacket and once warmed up could shed the jacket and we were right for the day.
MacPac jackets are brilliant. We did not have rain whilst on the hike however strong cold wind. The jacket provides another layer of warmth and protects you from the wind. Jacket has many pockets, zip from top and bottom and folds away into the hood.
We offer both men's and women's rain jackets but we know that some women prefer the shape and size of the men's models. You choose.


text:
Q: How to get text value from XML in Flutter I would like to know how to get the text value from an XML document in flutter. I know to use the XML dart library already just having trouble when it comes to parsing the variables.
For example:
The XML line: Bob
In my current parsing set up returns: (Bob)
How do I do it without the brackets?

A: UPDATE:
Instead of converting XML to JSON you can use the Flutter XML package (https://pub.dev/packages/xml)
Example:
XmlDocument xml = XmlDocument.parse('''
<?xml version="1.0" encoding="UTF-8" standalone="yes" ?>
<Results>
    <Person>
        <Name>Joe Blogs</Name>
        <Age>21</Age>
    </Person>
    <Person>
        <Name>Alexander Hamilton</Name>
        <Age>28</Age>
    </Person>
</Results>
''');

print(xml.getElement("Results")
    .firstElementChild.getElement("Person").getElement("Name").text);
print(xml.getElement("Results")
    .firstElementChild.getElement("Person").getElement("Age").text);

Output:
Joe Blogs
21

I would recommend this updated method as converting to JSON can incorrectly parse causing data loss.

OLD VERSION:
I managed to get around my issue with inspiration from @CopsOnRoad.
I parsed the XML data returned from the API to a JSON array using the Flutter package: https://pub.dev/packages/xml2json
And then managed to display it with arrays.
Example:
String xmlString = '''
<?xml version="1.0" encoding="UTF-8" standalone="yes" ?>
<!DOCTYPE root SYSTEM "rootDtd" "dtd/root.dtd">
<root>
    <element1>Child 1</element1>
    <element2>Child 2</element2>
    <element3>Child 3</element3>
    <element4>Child 4</element4>
    <element5>Child 5</element5>
    <element6>Child 6</element6>
    <element7>Child 6</element7>
</root>
''';
          Xml2Json xml2json = new Xml2Json();

          xml2json.parse(xmlString);
          var json = xml2json
              .toParker(); // the only method that worked for my XML type.

          print(json);
          var response = jsonDecode(json);
          print(response);
        } catch (JSONException) {}

redpajama_set_name: RedPajamaStackExchange


text:
Primary colonic well-differentiated / dedifferentiated liposarcoma of the ascending colon: a case report
Hiroshi Sawayama1,
Naoya Yoshida1,
Yuji Miyamoto1,
Tomoyuki Uchihara1,
Tasuku Toihata1,
Taisuke Yagi1,
Yukiharu Hiyoshi1,
Masaaki Iwatsuki1,
Yoshifumi Baba1 &
Hideo Baba ORCID: orcid.org/0000-0002-4270-76751
Primary colonic and dedifferentiated liposarcomas are both remarkably rare. This work describes a case of primary colonic well-differentiated/dedifferentiated liposarcoma and reviews the clinical characteristics and current therapies for liposarcoma tumors.
A 52-year-old woman was referred to our hospital with a submucosal tumor of the ascending colon. Clinical analysis by ultrasound colonoscopy and computed tomography revealed a partially ossified tumor with irregular edges continuous with the muscular layer. High F-18 deoxyglucose uptake was detected by positron emission tomography. Radical resection with lymph node dissection was performed, yielding a tumor specimen approximately 6.5 × 4.0 × 3.2 cm. Neoplastic spindle cell proliferation was found from submucosa to subserosa. Well-differentiated adipose tissue surrounded the tumor, but contained atypical nuclei with condensed chromosomes. Immunohistochemical staining was positive for p16, CDK4, and MDM2 expression. Based on these findings, a diagnosis of well-differentiated/dedifferentiated liposarcoma was given. Dedifferentiated liposarcomas are more aggressive than their well-differentiated, low-grade counterparts. While local recurrence can occur with both tumor types, dedifferentiated liposarcomas are more prone to developing distant metastases. The patient received no postoperative therapy, and no recurrences have been observed 12 months after surgery.
Here we report an extremely rare case of well-differentiated/dedifferentiated liposarcoma of the ascending colon. The dedifferentiated component was high-grade liposarcoma and well-differentiated liposarcoma was detected around the main tumor.
Soft tissue sarcomas arise from skeletal or extraskeletal connective tissue in the extremities, retroperitoneum, head and neck, and subcutaneous tissues. Liposarcoma is the single most common soft tissue sarcoma, accounting for at least 20% of all sarcomas and over 50% of retroperitoneal sarcomas [1]. The most recent World Health Organization classification recognizes five categories of liposarcomas: well-differentiated or atypical lipomatous tumor—which includes the adipocytic, sclerosing, and inflammatory subtypes; myxoid; high-grade myxoid; pleomorphic; and dedifferentiated [2]. Primary colonic liposarcoma is rare, while dedifferentiated liposarcoma is even more so. This report describes the surgical resection of a primary colonic well-differentiated/dedifferentiated liposarcoma and discusses the disease characteristics and current treatments.
A 52-year-old woman was referred to our hospital with a submucosal tumor of the ascending colon. The patient voiced no complaints, and no abnormalities were found upon physical examination. She had a past history of pulmonary tuberculosis at 22 years of age. Laboratory findings showed a slight elevation of carcinoembryonic antigen (CEA; 3.6 mg/mL; reference value, <3.4 mg/mL) and other values were normal. Colonoscopy confirmed a submucosal tumor extending from the hepatic flexure to the ascending colon (Fig. 1a), with edges continuous with muscular layer as determined by ultrasound colonoscopy. Biopsy was attempted, but the tissue could not be collected because of bleeding. Computed tomography (CT) revealed irregular tumor edges and highly dense areas indicative of calcification (Fig. 1b). The primary tumor standardized uptake value (SUVmax) for F-18 deoxyglucose was 2.4–3.4 as determined by positron emission tomography (Fig. 1c). Gastrointestinal stromal or neuroendocrine tumors were considered as a differential diagnosis.
Preoperative examinations. (a) A submucosal tumor extending from the liver flexure to the ascending colon was detected by colonoscopy. (b) Computed tomography showed irregular tumor edges and highly dense areas indicative of calcification. (c) The primary tumor standardized uptake value (SUVmax) of F-18 deoxyglucose was measured at 2.4–3.4 by positron emission tomography
We performed a radical resection with lymph node dissection. General anesthesia was induced with full muscle relaxation, and a skin incision was made in the abdomen. A firm tumor was confirmed in the ascending colon, but the abdominal cavity was devoid of metastatic or disseminated lesions. The ileocolic vein and artery, as well as an accessory right colic vein, were identified, ligated, and cut, and the main lymph nodes on the anterior surface of the inferior mesenteric vein from gastrocolic trunk to ileocolic vein were dissected. We resected along the fusion fascia between the mesocolon and retroperitoneum; the resultant surgical specimen completely encompassed a firm tumor.
The resected specimen was approximately 6.5 × 4.0 × 3.2 cm (Fig. 2a, b), the center of the solid tumor being located in the middle of the resected specimen. Pathologic examination revealed proliferating spindle cells from the submucosa to subserosa (Fig. 2c, d), as well as partial ossification. The mitotic rate was eight mitoses/10 high-power fields. No necrotic areas were detected, and the tumor was not encapsulated. Well-differentiated adipose tissue surrounded the tumor, but contained atypical nuclei with condensed chromosomes (Fig. 2e). Immunohistochemistry was positive for p16, CDK4, and MDM2 expression (Fig. 3a–d). Based on these clinicopathological findings, the tumor was classified as well-differentiated/dedifferentiated liposarcoma.
Resected specimen and pathological findings. (a, b) The resected tumor was 6.5 × 4 × 3.2 cm (83.2 cm3). (c) Proliferating spindle cells from the submucosa to subserosa. (d) Dedifferantiated sarcoma: tumor histopathology revealed proliferating neoplastic spindle cells. (e) Well differentiated liposarcoma: atypical nuclei was detected with condensed chromosomes (arrows)
Immunohistochemistry for p16, CDK4, and MDM2 expression. (a) Hematoxylin eosin stain. Immunohistochemistry of (b) MDM2, (c) p16, and (d) CDK4
A firm mass of dedifferentiated sarcoma was completely resected. However, there were some atypical cells in the adipose tissue around the firm tumor and these were diagnosed as well differentiated liposarcoma. The well-differentiated liposarcoma component extended to the surgical margin in places; however, only normal adipose tissue was detected at most of the surgical margin. A positive surgical margin was detected only for the parts of the well differentiated sarcoma near the firm mass. No lymph node metastasis was detected. Microscopic remnant of well-differentiated liposarcoma was confirmed according to pathological findings, but post-surgical FDG-PET CT and enhanced CT could not detect the remnant tumor around the resected lesion. The patient received no postoperative therapy. We performed follow-up evaluation with enhanced computed tomography or magnetic resonance imaging every 3 months. No recurrences have been observed 12 months after surgery.
This report describes an extremely rare case of ascending colonic well-differentiated/dedifferentiated liposarcoma. PubMed was queried for articles published in English from January 1990 to September 2016 with the terms "liposarcoma" and "colon". Seventy-six articles were returned, of which 13 and 2 described primary colonic well-differentiated and dedifferentiated liposarcoma, respectively. Primary colonic liposarcoma is rare, and only a few cases of dedifferentiated liposarcoma have been reported [3, 4]; therefore, considerations of the characteristics and treatments of primary colonic liposarcoma generally reference those for retroperitoneal tumors.
Dedifferentiated liposarcomas arise from their well-differentiated counterparts and thus exhibit cytogenetic similarities. Immunohistochemistry for CDK4, MDM2, and p16 expression aids in the differential diagnosis of well-differentiated and dedifferentiated liposarcoma from other adipocytic neoplasms [5]. Despite this, the two display significantly different biologic behaviors. Low-grade, well-differentiated tumors can recur as high-grade, dedifferentiated disease characterized by increased local recurrence rates and metastatic potential. For instance, retroperitoneal well-differentiated and dedifferentiated liposarcomas were associated with 3-year local recurrence rates of 31% and 83%, respectively. Approximately 20–30% of dedifferentiated liposarcomas result in distant recurrence, as opposed to only 3% of well-differentiated tumors—of which all belonged to the sclerosing subtype. Moreover, dedifferentiated liposarcoma is associated with a 4–6-fold increased risk of death when compared with well-differentiated cases [6, 7].
In this case, the dedifferentiated liposarcoma formed a firm mass that was easily identified; however, the well-differentiated sections were soft and difficult to distinguish from the fat tissue surrounding the ascending colon during the operation. We therefore recommend that when dedifferentiated liposarcomas are resected, an adequate margin of soft fatty tissue around the solid tumor also be resected to ensure that no well-differentiated liposarcoma remains. Given that it is difficult to diagnose dedifferentiated liposarcoma preoperatively, submucosal tumors suspected of being high-grade sarcomas need to be resected with adequate margins that include soft tissue around the firm tumor.
Positive margins increase the risk of local recurrence, their influence on overall survival is less clear. Positive microscopic margins (R1) are reportedly associated with higher distant recurrence rates and poorer prognoses than negative microscopic margins (R0) [8], but other studies have failed to demonstrate this relationship [6, 9]. Moreover, 72% of patients with positive margins had no recurrence [8]. Positive margins were poor prognosis than negative margins in the high-grade tumor; however, surgical margins were not related with prognosis in the low-grade tumor [7].
Postoperative treatment for liposarcoma remains controversial. Adjuvant radiotherapy limits the risk of local recurrence, but no definite survival benefit has been established [10] and patients often experience severe adverse effects attributed to cell death in the surrounding normal tissues—primarily the small bowel [11]. In 1054 patients undergoing resection of primary retroperitoneal sarcoma, 276 patients underwent radiotherapy. But the radiotherapy had no significant impact on prognosis (HR, 0.95; 95% CI, 0.78–1.15; P = 0.6) [12]. Recent study reported the survival benefits of adjuvant radiotherapy, but the postoperative radiotherapy effect does not depend on surgical margin status (HR 0·93; 95% CI 0·79–1·10; P = 0.38) [13]. Comparatively, adjuvant chemotherapy with a doxorubicin-based regimen ((EORTC 62771: doxorubicin, dacarbazine, cyclophosphamide and vincristine; EORTC 62931: doxorubicin and ifosfamide) is an independent favorable prognostic factor for relapse-free, but not overall, survival [14, 15]. In this case, low-grade, well-differentiated liposarcoma were positive but dedifferentiated liposarcoma was completely resected, and no adjuvant therapy was given based on previous studies.
The following recommendations for evaluation during follow-up of retroperitoneal sarcoma have been published by the Trans-Atlantic RPS Working Group. Because the median time to recurrence of high-grade retroperitoneal sarcoma is less than 5 years after definitive treatment, the intervals between follow-up evaluations should be 3 to 6 months for 5 years. After 5 years, annual follow-up is considered adequate. After incomplete resection of retroperitoneal sarcoma patients should be followed indefinitely because the risk of recurrence does not plateau [16].
This report describes an extremely rare case of ascending colonic liposarcoma consisting of well-differentiated and dedifferentiated sections. Dedifferentiated liposarcomas are high-grade sarcomas; additionally, well differentiated liposarcoma was detected around the main tumor. The dedifferentiated tumor was completely resected, but the aggressive nature of dedifferentiated liposarcoma need periodic examination.
CDK4:
Cyclin-dependent kinase 4
Confidential interval
FDG:
F-18 deoxyglucose
MDM2:
Murine double minute 2
Positron emission tomography
SUV:
Standardized uptake value
Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer. 1995;75:211–44.
Fletcher CBJ, Hogendoorn P, Mertens F. World Health Organization classification of tumours of soft tissue and bone: pathology and genetics of tumours of soft tissue and bone. 4th ed. Lyon, France, IARC Press; 2013.
Turkoglu MA, Elpek GO, Dogru V, Calis H, Ucar A, Arici C. An unusual case of primary colonic dedifferentiated liposarcoma. Int J Surg Case Rep. 2014;5:8–11.
Takeda K, Aimoto T, Yoshioka M, Nakamura Y, Yamahatsu K, Ishiwata T, et al. Dedifferentiated liposarcoma arising from the mesocolon ascendens: report of a case. J Nippon Med Sch. 2012;79:385–90.
Thway K, Flora R, Shah C, Olmos D, Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012;36:462–9.
Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358–70. discussion 370-351
Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008;15:2739–48.
Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424–34.
Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003;97:2544–53.
Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG. Retroperitoneal soft tissue sarcoma. Cancer. 2005;104:669–75.
Pawlik TM, Ahuja N, Herman JM. The role of radiation in retroperitoneal sarcomas: a surgical perspective. Curr Opin Oncol. 2007;19:359–66.
Nathan H, Raut CP, Thornton K, Herman JM, Ahuja N, Schulick RD, et al. Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg. 2009;250:970–6.
Nussbaum DP, Rushing CN, Lane WO, Cardona DM, Kirsch DG, Peterson BL, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol. 2016;17:966–75.
Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25:2425–32.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.
Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Annals of surgical oncology 2015;22:256–263.
The authors thank Dr. Yoshiki Mikami for the pathological diagnosis.
The authors declare that this study was not funded.
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan
Hiroshi Sawayama, Naoya Yoshida, Yuji Miyamoto, Tomoyuki Uchihara, Tasuku Toihata, Taisuke Yagi, Yukiharu Hiyoshi, Masaaki Iwatsuki, Yoshifumi Baba & Hideo Baba
Hiroshi Sawayama
Naoya Yoshida
Yuji Miyamoto
Tomoyuki Uchihara
Tasuku Toihata
Taisuke Yagi
Yukiharu Hiyoshi
Masaaki Iwatsuki
Yoshifumi Baba
HS performed the surgery, acquisition of data, interpretation of data, and drafting of the manuscript. NY, YM, TU, UU, TY, YH, MI, and YB contributed to the critical revision of the manuscript for important intellectual content intellectual content. HB contributed study supervision. All authors read and approved the final manuscript.
Written informed consent for the operative methods was obtained from the patient, and informed consent was also obtained from the patient for publication of this case report and any accompanying images.
Sawayama, H., Yoshida, N., Miyamoto, Y. et al. Primary colonic well-differentiated / dedifferentiated liposarcoma of the ascending colon: a case report. surg case rep 3, 96 (2017). https://doi.org/10.1186/s40792-017-0373-4
Primary colon
Dedifferentiated liposarcoma
Well-differentiated liposarcoma
CDK4
MDM2


A beautiful free-form Baltic amber heart pendant, sterling silver bale. These heart pendants are highly polished pieces of GRADE A Baltic Amber. Color varies from honey to cognac/darker honey. Approximately 1" long. The photo does not do this pendant justice.
Gift pouch, jewellery cording and amber authenticity card included.


Jays in the House: Hall of Shame?
Jeff Bagwell, who spent his entire career in Houston, just entered the HOF despite being suspected of steroid use in the 90s.
The Steroid Era and the Hall of Fame. What a conundrum.
You probably read about Jose Canseco's series of Tweets on the matter earlier this week. You have to admit the guy has a point. The Edward Snowden of MLB PEDs was not thrilled by the fact Bagwell got into the HOF while McGwire languishes as a bench coach for the lowly Padres without the honour.
Personally I had always thought "Good for them, screw the cheaters". Bonds, Clemens and McGwire, both with first ballot career numbers, being kept out of the HOF was their just desserts. Cheaters should suffer. But, were they allowed to get away with it?
The Sosa and McGwire HR battle was huge for the MLB. It got McGwire on The Simpsons again. Great for TV ratings after the strike. Bud knew what he was doing. He moved his Brewers knowing they make more money in the NL. This crook was inducted into the HOF this year as well.
I have to also mention that Tim Raines admitted keeping a gram of coke in his uniform pocket (as well as revealing that he snorted during games), and that he only slid into bases headfirst so as not to break the vial.
Canseco argues if you let one PED user in you should have to let them all in. What do you think?


Here is another alpha release: 2.5.0-alpha4. It has numerous improvements and bug fixes comparing to the previous unstable version released one and a half year ago. As you can see from the changelog most changes were made by contributors, not me. You can see there most of the patches posted/mentioned on the forum. There is the play queue, lyrics displaying, the equalizer and more.
There are also some fixes in this release that are not present in the stable version, I hope to find time to merge them soon.
Tags cache using BerkeleyDB for better perfomance, reliability and smaller memory usage.
Add .oga extension to formats supported by the vorbis plugin.
Fix race condition when waiting for the end of a file playback. Fixes freez on song changes.
Change minimum screen height to 7 lines. (Tero Marttila).
For whatever it's worth, thanks to all of those who brought us this release. When I have some free time, I'm hoping to work on some of those TODOs myself.
My locale is en_US.UTF-8, and I've got 2.5.0-alpha3 (Debian Stable). The file has only id3v2 tags.
Will upgrading to alpha4 fix this? It's not compiling for me and I don't want to bother if it won't fix the issue.
Can you add a new options?
I use mocp on my home freebsd server. I'd like to write a web interface to control the player with the CGI, but I am missing a few arguments for mocp client.
For example, not enough keys for enable/disable repeat and shuffle. I would also like to see the key to display the playlist in the console, without using the GUI.
I would be happy to see these options in the next stable version of the player.
Time is always the problem.


Applian User Forums > General Discussions > General Discussion > Your web hosting provider?
View Full Version : Your web hosting provider?
I apologize for the possible off-topic. Guys, could you tell me which web hosting company you are using at the moment? I have a problem because my current web hosting company *** is kicking me off. They say that our website is using too many server resources. But our website only gets 300 visitors per day..
I am checking ***** at the moment, but is it real that they can provide unlimited disk space?
We actually just switched our server provider from Verio to a private entity. For your size, a Verio or other large company would not make sense. I'd follow through with the hosting company you contacted given your realtively small server needs.
There are lots of web-hosting providers that offer unlimited disk space and unlimited traffic. In reality you are always limited by the server load that is produced by your web-site(s).


text:
Q: SQLServerException: The TCP/IP connection to the host localhost, port 1433 has failed. I am running Ubuntu 16.04 and using SQL Server Express and Oracle Java 9:
$ java --version
java 9.0.1
Java(TM) SE Runtime Environment (build 9.0.1+11)
Java HotSpot(TM) 64-Bit Server VM (build 9.0.1+11, mixed mode)

I have installed SQL Server jdbc driver (sqljdbc_6.2.2.0_enu.tar.gz in https://www.microsoft.com/en-us/download/details.aspx?id=55539)
/home/t/program_files/RDBMS/JDBC/mssqlserverjdbc_6.0/enu/jre8/sqljdbc42.jar

I wrote some simple   code to test using the driver :
// JDBC driver name and database URL
String JDBC_DRIVER = "com.microsoft.sqlserver.jdbc.SQLServerDriver";
// static final String DB_URL = "jdbc:mysql://localhost/"; // connect to a DBMS
String DB_URL = "jdbc:microsoft:sqlserver://localhost/STUDENTS"; // connect to a specific database in a DBMS
//  Database credentials
String USER = "SA";
String PASS = "password";

//Register JDBC driver
try{
    Class.forName(JDBC_DRIVER);
}catch(Exception e){ //Handle errors for Class.forName
    e.printStackTrace();
}

    //Open a connection
System.out.println("Connecting to database...");

try(Connection conn = DriverManager.getConnection(DB_URL, USER, PASS); // connect to DBMS, not to a DB
    Statement st = conn.createStatement()){

}catch(SQLException se){ //Handle errors for JDBC
    se.printStackTrace();
}

Compilation is fine:
$ javac BasicOperations.java

Running isn't.
$ java -cp .:/home/t/program_files/RDBMS/JDBC/mssqlserverjdbc_6.0/enu/jre8/sqljdbc42.jar BasicOperations
Connecting to database...
com.microsoft.sqlserver.jdbc.SQLServerException: The TCP/IP connection to the host localhost/STUDENTS, port 1433 has failed. Error: "localhost/STUDENTS. Verify the connection pro\
perties. Make sure that an instance of SQL Server is running on the host and accepting TCP/IP connections at the port. Make sure that TCP connections to the port are not blocked \
by a firewall.".
        at com.microsoft.sqlserver.jdbc.SQLServerException.makeFromDriverError(SQLServerException.java:191)
        at com.microsoft.sqlserver.jdbc.SQLServerException.ConvertConnectExceptionToSQLServerException(SQLServerException.java:242)
        at com.microsoft.sqlserver.jdbc.SocketFinder.findSocket(IOBuffer.java:2369)
        at com.microsoft.sqlserver.jdbc.TDSChannel.open(IOBuffer.java:551)
        at com.microsoft.sqlserver.jdbc.SQLServerConnection.connectHelper(SQLServerConnection.java:1963)
        at com.microsoft.sqlserver.jdbc.SQLServerConnection.login(SQLServerConnection.java:1628)
        at com.microsoft.sqlserver.jdbc.SQLServerConnection.connectInternal(SQLServerConnection.java:1459)
        at com.microsoft.sqlserver.jdbc.SQLServerConnection.connect(SQLServerConnection.java:773)
        at com.microsoft.sqlserver.jdbc.SQLServerDriver.connect(SQLServerDriver.java:1168)
        at java.sql/java.sql.DriverManager.getConnection(DriverManager.java:678)
        at java.sql/java.sql.DriverManager.getConnection(DriverManager.java:229)
        at BasicOperations.main(BasicOperations.java:46)

How shall I solve the problem? Is it correct that I should do equivalence to  https://stackoverflow.com/a/12430561/1224441 on Ubuntu?
Because I am using SQL Server Express on Ubuntu, I only know how to access it on terminal using sqlcmd.
Thanks.


Supertrans Logistics provides International freight transportation/logistics services for freight all kinds from China to Singapore.
While shipping from China to Singapore, Supertrans Logistics provides all necessary logistics solutions to satisfy your needs at competitive shipping rates as well as excellent services.
With strong support of our cooperating offices/agents in each port of China, we handle sea freight services including FCL (full container load) and LCL (less than container load), out of Gauge, Roll on Roll off, etc. Air freight comprises a program of scheduled and deferred services to and from China with coverage via all major airports.
Exact shipping documentation, customs clearance and complete handling of your import or export goods are part of the product pallet of Supertrsans Logistics.
We have been managing shipments like textile, Semiconductor, clothing and electronic products from China to Singapore for years' of experience. No shipment is too large or small for us! Except for general delivery, a full door to door service is also available - from time of order placement to final delivery, we are in complete control of your freight.
Through continuous improvement, we consistently devise new freight models and innovative solutions to meet your ever-changing business needs.


What is an example of some of the leadership characteristics and responsibilities within policing organizations? How do these leadership characteristics translate into overall organizational effectiveness? What recommendations would you suggest so that policing organizations are more successful?


text:
German nurse who killed at least 85 patients jailed for life
By Sheena McKenzie and Claudia Otto, CNN
Updated 7:55 AM ET, Thu June 6, 2019
Niels Hoegel, a former nurse who has admitted to the killing of 100 patients, is seen in court in Oldenburg, Germany, in March.
(CNN) A German serial killer nurse was jailed for life on Thursday for the murder of 85 patients in his care, according to a statement from a court in the northwest city of Oldenburg.
Niels Hoegel, a 42-year-old former nurse who is considered Germany's deadliest post-war serial killer, was sentenced to life in prison at the District Court of Oldenburg.
While summing up the trial, the judge said Hoegel's actions were "incomprehensible: That's the word that characterizes this."
The health worker had previously confessed to killing 100 patients -- aged between 34 and 96 years old -- at two hospitals in northern Germany between 2000 and 2005. However Hoegel was acquitted of 15 cases on Thursday because there was not enough evidence.
Hoegel was accused of giving his victims various non-prescribed drugs, in an attempt to show off his resuscitation skills to colleagues and fight off boredom.
In past hearings, Hoegel said he felt euphoric when he managed to bring a patient back to life, and devastated when he failed.
Police suspect the true death toll may be as high as 200, but can't be certain as many patients were cremated before autopsies could be performed, reported Agence France-Presse news (AFP) agency.
The former nurse is already serving a life sentence for six convictions, including homicide and attempted homicide in 2008 and 2015. Those convictions led authorities to investigate hundreds of deaths and exhume the bodies of former patients in the clinics where he worked.
Hoegel asked his victims' families for forgiveness on Wednesday for his "horrible acts."
"I would like to sincerely apologize for everything I did to you over the course of years," he said during the hearing, AFP reported.
'Collective amnesia'
One of the biggest questions in the case is how Hoegel was able to murder so many people apparently under the watch of hospital staff.
Former colleagues at the Delmenhorst clinic where he worked admitted to having had their suspicions about Hoegel, according to AFP. But all the staff from the other hospital in Oldenburg who testified said they were oblivious to the rising death toll.
During sentencing Judge Sebastian Buehrmann criticized what he called staff's "collective amnesia," adding that Hoegel's killing spree was "incomprehensible."
About 126 relatives of the victims are co-plaintiffs in the trial, which has been running since October 2018.
CNN's Atika Shubert contributed to this story.


So I've been terribly remiss in my OG blogging lately. Partly this is because I'm just incapable of saying anything interesting about politics. Partly it's because I've been so focused on my video game writing at Forbes. And partly it's because I'm pretty sure my family has been sick with a cold or a stomach virus every single week for the past…three, four months? I've lost track.
The song is rough-draft-ish and the sound is very lo-fi. Hope you enjoy.
Nice! The chorus melody reminds me a little of the Shins. Hopefully that's taken as a compliment, it's meant as one; even though I don't listen to the band very frequently, I always enjoy them when I do. They usually had sharp twisty melodies that are fairly unique-sounding – you can hear a little bit of the Beach Boys or Zombies or Smiths in there, but mostly they just sound like the Shins.
Erik, did you use your new mic to record the guitar or have an internal pick-up? If the mic, then it's a nice one; not much in the way of string squeak, etc., which is often a problem with external mics.
I spent too much time in college with folks who had guitars. I only listened to this with great apprehension, flashing back to open mic night.


text:
G & L Wellness, LLC - 609572 - 12/22/2020
G & L Wellness, LLC MARCS-CMS 609572 — December 22, 2020
Lois Carter
Recipient Title
G & L Wellness, LLC
2231 14th St S 114
Wisconsin Rapids, WI 54494
content@glwellness.net
Center for Drug Evaluation and Research | CDER
RE: 609572
Dear Ms. Carter:
This letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.glwellness.net in August and December 2020 and has determined that you take orders there[1] for the "C BETTER DAILY Adult Regular Formula," "C BETTER DAILY Adult Maximum Formula," and "C BETTER DAILY Soothing Formula," (hereinafter collectively referred to as "your C BETTER DAILY products for humans") all of which you promote as eye drop products containing cannabidiol (CBD) for human use. The claims on your website establish that your C BETTER DAILY products for humans are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). FDA has also determined that you take orders for the product "C BETTER DAILY Pet Formula" on your website at www.glwellness.net. This product, which you promote as an eye drop product containing CBD, is an unapproved new animal drug that is unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).
These products are especially concerning from a public health perspective because ophthalmic drug products can pose serious risk of harm to humans and/or animals if toxic substances are introduced directly into the eye because irreversible damage, including vision loss, can result.
As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA's home page at www.fda.gov. You can find specific information about how FDA regulates CBD at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.
Unapproved New Drugs
Based on our review of your websites, your C BETTER DAILY products for humans are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.
Examples of claims observed on your website www.glwellness.net and/or label of your products that establish their intended uses as drugs include, but may not be limited to, the following:
On your product label for "C BETTER DAILY Adult Maximum Formula":
"MULTI SYMPTOM EYE CARE"
On your product webpage for "C BETTER DAILY" at your website www.glwellness.net, you state:
Under a rotating banner titled "C BETTER DAILY":
"C Better Daily is the hemp industries first and only multi-symptom eye care solution."
"A harmonic blend of herbal extracts chosen for their ability to reduce swelling, itching and inflammation."
Under "Intended for Daily Use":
"Organic chamomile hydrosol is the base of all our formulas, chosen for its long-standing history of traditional use as an anti-inflammatory, antioxidant and mild astringent."
Under "Research":
"G & L Wellness had introduced the world's first and only hemp derived multi symptom eye care solution for both people and pets and they quickly started to make their way across the country and the world!"
"Applications of CBD as an anti-inflammatory, anti-bacterial, neuroprotective and vasodilator compound are well researched and documented."
"Both minor and major eye related issues are beginning to be clinically researched as to what role the ECS [endocannabinoid system] and the receptors, enzymes and endocannabinoids within play to the overall health and longevity of our eyes."
"N-Acetylcysteine (NAC) is present in three of our formulas, Maximum, Regular and Pet in various concentrations. It is a powerful antioxidant. Among ocular research, you will discover that this amino acid is reviewed throughout clinical studies for its effect on cataracts, macular degeneration, dry eye, facilitation of wound healing in damaged corneal epithelial cells and other degenerative eye diseases . . . It is often used as a dietary supplement or as an ingredient incorporated into medications, for example, as an inhalant used by pulmonary specialists in the treatment of cystic fibrosis."
Your C BETTER DAILY products for humans are not generally recognized as safe and effective for their above referenced uses and, therefore, these products are "new drugs" under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a) unless they are over-the-counter (OTC) drugs lawfully marketed under section 505G of the FD&C Act (which is not the case for these products). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. There are no FDA-approved applications in effect for any of the above-mentioned products.
Misbranded Drugs
Your C BETTER DAILY products for humans are also misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, under 21 CFR 201.100(c)(2) and 201.115, because no FDA-approved applications are in effect for them. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).
Unapproved New Animal Drugs
During our review of your firm's website www.glwellness.net, FDA determined that your firm is marketing the unapproved new animal drug "C BETTER DAILY Pet Formula." Based on our review of your website, your "C BETTER DAILY Pet Formula" product is a drug under section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. Further, as discussed below, this product is an unapproved new animal drug and marketing it violates the FD&C Act.
Examples of claims observed on your website www.glwellness.net that establish the intended uses of this product include, but may not be limited to, the following:
On your product webpage for "C BETTER DAILY Pet Formula" at your website www.glwellness.net, you state:
Under a rotating banner titled "C BETTER DAILY Pet Formula":
"[T]he world's first and only hemp derived multi symptom eye care solution for both people and pets…"
Under "Consumer Commonly Asked Questions":
"Ingredients in C Better Daily may reduce pain, inflammation and redness…"
Your "C BETTER DAILY Pet Formula" product is a "new animal drug," as defined by section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because it is not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-l. Your "C BETTER DAILY Pet Formula" product is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of this adulterated drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).
The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
You should take prompt action to address the violations cited in this letter. Failure to promptly address violations may result in legal action without further notice, including, without limitation, seizure and/or injunction.
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so.
Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research/Office of Compliance/Office of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 or by e-mail to FDAADVISORY@fda.hhs.gov.
Donald D. Ashley
Office of Compliance
Center for Drug Evaluation and Research
Director of Compliance
Office of Surveillance & Compliance
Center for Veterinary Medicine
[1] In addition to taking orders from your website at www.glwellness.net, we also observed that you direct consumers to the website www.proteambrady.com to purchase your products. By directing consumers to www.proteambrady.com to purchase your products, your firm is responsible for causing the introduction or delivery into interstate commerce of products that are unapproved new drugs and misbranded under section 505(a) of the FD&C Act and/or misbranded under 502 of the FD&C Act, which is prohibited under sections 301(a), (d), and (k) of the FD&C Act, 21 U.S.C. 331(a), (d), and (k).
Regulated Product(s)


Investexo accepts investments with e-currencies and promises high yield return (probably).
Individuals from all over the world are welcome to join Investexo (probably).
Extensive details about Investexo has not yet been specified by investexo.com owner.
So, we not yet know specific information about Investexo investment plans and terms.
Possibly Investexo review can be found in comments section below.
If you know more about investexo.com services and performance, please comment on Investexo.
Investexo owner is invited to enter details and we will publish investexo.com summary for free.
If there is something wrong with Investexo, please submit problem report.


text:
El Himno a Guerrero, dedicado a Vicente Guerrero consumador de la Independencia Nacional. La música fue por Margarito Damián Vargas y el autor de la letra es Francisco Figueroa Mata que fuera gobernador provisional, primero, y, después, sustituto del estado, en el periodo 1918 a 1921.

Himno a Guerrero

Véase también
 Guerrero
 Himnos de los estados de México
 Escudo de Guerrero

Referencias

Enlaces externos

Símbolos de Guerrero
Himnos de los estados de México

redpajama_set_name: RedPajamaWikipedia


Fantasy Football Team of 12 Players sculpted by Franarcilla and made by Meiko Miniatures. The item is brand new and in perfect condition. Made with metal. The figures are supplied unpainted and unassembled. Twelve round 32 mm bases included.
Players included in the team: Kaos Warrior nº 1, Kaos Warrior nº 2, Kaos Warrior nº 3, Kaos Warrior nº 4, Beastman nº 1, Beastman nº 2, Beastman nº 3, Beastman nº 4, Beastman nº 5, Beastman nº 6, Beastman nº 7 and Beastman nº 8. None of them is repeated, they're all different from each other!
If you wish you may also get 4 Mutated Evil Warriors (Two Heads, Strong Arm, Crab Claws and Demon Possessed), also available at our store.
If you wish you may also get 4 Mutated Beastmen (Two Heads, Multiple Arms, Crab Claws and Mechanical Claw) and 4 alternative Demon Beastmen (Transformation Demon, Blood Demon. Pleasure Demon and Putrid Demon), also available at our store.


Viparita karani, or "Legs-up-the-Wall Pose" (viparita means "inverted" and karani means "doing") is a powerfully restorative posture. It is a variation of the Shoulderstand. In fact, this pose can be an alternative inverted posture for those men who find the Shoulderstand too challenging. Legs-up-the-Wall Pose helps to relieve backache while providing the stimulating benefits of an inverted posture, helping to promote good circulation, particularly in the legs and feet. In addition to being practiced as part of a complete yoga workout, yoga postures can be practiced individually for their specific benefits whenever and wherever you have the time and inclination to do them: Try this posture when you come home from work and want to relax and renew yourself after a stressful day. Follow the example set by the model in Fig. 13.3: take off your shoes, loosen your belt, and invert your legs up the wall.
In viparita karani, you'll be lying on the floor on your back with your legs supported above you on the wall. You may wish to have a pillow or other padded prop handy to support your lower back and hips in this position. First, find a comfortable, padded space on the floor next to a wall where you'll be able to place your legs. Sit sideways against the wall with your right side facing the wall, about five to six inches away from it. As you exhale, swivel your buttocks toward the wall as you simultaneously lift your legs straight against the wall and lower your upper body so that your back is on the floor. Check to see how this placement of your body against the wall feels. If you are stiff, or tall, you may need to slide your buttocks slightly farther from the wall. You can also try placing a pillow or other padded prop under your buttocks for additional support. Experiment until you find a comfortable position. Don't be discouraged if it seems difficult to get into position on the first few tries. You are using Fig. 13.3: Legs-up-the-Wall Pose your body in a new way, and it can take time to develop the kinesthetic sense to do the pose comfortably. This pose is deeply restorative and is well worth the effort to experiment with it. Stay in this position for a few minutes to begin and gradually increase your time in the position for up to 15 to 20 minutes. As you perform Legs-up-the-Wall Pose, allow your sternum to lift toward your chin. Avoid any strain on the neck.


text:
HomeRegulatoryPacran Receives Natural Product Number From Canada
Pacran Receives Natural Product Number From Canada

Naturex’s Pacran®, a natural solution for urinary comfort, received a Natural Product Number from Health Canada.

SOUTH HACKENSACK, N.J.—Naturex's Pacran®, a natural solution for urinary comfort, received a Natural Product Number (NPN) from Health Canada.
With a minimum daily dose of 500 mg, all finished products using Pacran can make claims such as "helps prevent recurrent urinary tract infections in women," or "used in herbal medicine to help prevent (recurrent) urinary tract infections".
Urinary tract infections (UTIs) are a universal problem, with nearly half of all women suffering from a UTI at some point in their lives, and nearly one in three of those women suffering from recurrent UTIs within one year. Formulators are challenged with selecting the right ingredient for their urinary tract health products.
The new approval reinforces the renown of Pacran, which already has a Health Functional Food Ingredient Certificate in South Korea, allowing all finished products to claim: "can help urinary tract health by inhibiting adherence of harmful bacteria to urinary tract".
"The recent health claim approvals from Canada and South Korea independently validate the strength of the scientific substantiation that we've built in support of Pacran," said Dan Souza, senior director of sales and marketing for Naturex-DBS.
Pacran is a 100-percent all-natural full spectrum cranberry ingredient supported by eight efficacy and safety studies. A daily dose of 500 mg of Pacran has been shown to reduce the rate of recurrent UTIs, reduce E. coli - the bacteria responsible for 65 to 85 percent of UTIs –in vivo and deliver E.coli anti-adhesion in ex vivo trials. This evidence drove Pacran's recent health claim approvals.
TAGS: Archive Herbs & Botanicals Women's Health


Bringing your girls down for their (and your) first princess experience is a memorable event!
Of all the deluxe resorts, this has the most princess-friendly theming. Character meals with Cinderella and Mary Poppins are here, as well as a princess tea party event.
The new Princess themed Royal Guest Rooms provide an over-the-top atmosphere in a still-budget friendly setting.
While Ariel has a section here, you may still prefer to lose a bit of the princess theme for one of the Family Suites.
As for must do events, a princess character meal is a nice treat. Cinderella's Royal Table is the long time favorite. But if they have a particular favorite, there might be other options. For instance the Cinderella Happily Ever After Dinner at 1900 Park Fare has more characters from that movie.
Make sure you are ready for character meet-and-greets throughout the parks. Check your My Disney Experience app for times and locations.
A final suggestion that is very popular is Bibbidi Bobbidi Boutique. It is not for my girls, but it might be a great final twist to the trip for yours?
Write me back if you want to ask any further questions to a dad in the same boat as you!


Hazard: The sound machine's internal battery can leak and cause an electrical short, posing a burn hazard.
Marpac at 800-999-6962 from 8:30 a.m. to 5:00 p.m. ET Monday through Thursday and 8:30 a.m. to 12:00 p.m. ET Friday, email at customerservice@marpac.com or online at https://marpac.com/ and click on "recall notice" for more information.
This recall involves Marpac Go travel sleep sound machines. The multi-use sound machine produces numerous different types of sound that block out distracting noise. The sound machine is white with a gray flip stand, an internal rechargeable battery, and comes with a USB cable. It measures about 3 inches high by 2 inches wide with the serial number located on a sticker on the back of the machine. The recalled units have a serial number range GT184600000 through GT184605200.
Sold At: Online at marpac.com, amazon.com, amazon.co.uk, harriscomm.com, and bedbathandbeyond.com from January 2019 through February 2019 for about $40.
Importer/Distributor/Manufacturer: Marpac, LLC, of Wilmington, N.C.


Another year and another Parliament Hill Ice Swim Hootenanny, PHISH 19th Jan 2019, at Brockwell Lido's sister in North London.
This year under new management, the event was just as good, well organised and well attended as previous years. Well done to Jeremy Irvine and his team for pulling off another stonking event with the pool at a perfect 5°C, a deliciously steaming giant hot tub and a sauna heated to the perfect temperature. What more could we ask for?
Our Brockwell Swimmers Relay Team, Jerry, Tim, Karen (birthday girl) and Peter took to the water promptly at 12:50 and carried on the tradition of successfully coming last in our heat… result! However, in total we didn't do too badly coming 16th out of 24 overall. Quite respectanble. This bodes well for our three relay teams entered in the Tooting Cold Water Championships in seven days time.
It was so good to see one of the few remaining unheated London Lidos celebrating the joy of Cold Water Swimming and pulling in so many hardened athletes from all over the UK. A wonderful networking opportunity with other like minded souls swapping stories from all over the country. Maybe one day Brockwell management will let us do the same at our own Lido? At the moment we are missing out on all the fun.


text:
Caratteristiche tecniche
È un difensore centrale.

Carriera

Club
È cresciuto nelle giovanili dello .

Statistiche

Presenze e reti nei club
Statistiche aggiornate al 6 gennaio 2017.

Cronologia presenze e reti in Nazionale

Palmarès

Club

Competizioni nazionali
 Srpska Liga Ovest: 1
Sloga Kraljevo: 2010-2011

Partizan: 2018-2019

Altri progetti

Collegamenti esterni

Calciatori della Nazionale serba


The demand for tert-butanol stems from its varied applications such as in paints and coatings, food flavoring, and fragrances.
The global tert-butanol market could be appropriately categorized based on end use and geography. By region, Asia Pacific holds dominance in terms of revenue generation.
The report on the global tert-butanol market prepared by expert analysts looks into every possible aspect that could influence the market's growth over the forecast period. The highlight of the report is a brilliant assessment of the growth behavior of key segments under different categories.
Tert-butanol finds varied application such as in paints and coatings, fragrances, and food flavoring across several end-use industries. Rapid industrialization and urbanization in emerging economies of Asia Pacific have led to massive growth of building and construction sector. This has indirectly influenced the growth of tert-butanol market for its application in paints and coatings that are extensively used in the building and construction sector. The construction of hospitals, amusement parks, schools, and public amenities have been surging in emerging economies of Asia Pacific, Latin America, and the Middle East and Africa.
Further, economic growth leading to rising disposable incomes in emerging economies has upped the demand for automobiles. Vehicle production has risen significantly over the past few years due to rapid urbanization and increasing vehicle ownership in several developing countries. This is indirectly driving the growth of tert-butanol market for paints and coatings applications.
The growing population in Asia Pacific along with rising consumption of processed foods is also boosting the demand for tert-butanol for food flavoring applications. Tert-butanol is used as a solvent and a flavoring agent in the food and beverages industry.
Tert-butanol also finds application in perfumes and personal care products. The pharmaceuticals segment is anticipated to display the leading growth rate vis-à-vis volume and revenue in the upcoming years.
On the flip side, however, regulations in place pertaining to volatile organic compound emissions have challenged the growth of the tert-butanol market to some extent. Nevertheless, these restrictions have compelled market players to develop bio-based variants. This is anticipated to provide growth opportunities to serve the demand for environment-friendly products.
Asia Pacific stands as the leading regional market for tert-butanol on the back of rising demand for tert-butanol for paints and coatings from automobile and construction sectors, and for application in flavors from the expanding processed food industry. Powered by China, India, and Japan Asia Pacific is also anticipated to be display speedier growth among other key regional markets over the forecast period.
The tert-butanol markets in North America and Europe are mature, and thus will display average growth by 2024. While Latin America tert-butanol market is likely to expand display notable growth, the Middle East and Africa tetra-butanol market is likely to display moderate growth in the upcoming years.
Some of the core companies functioning in the global tert-butanol market are LyondellBasell Industries Holdings B.V., Evonik Industries AG, Lotte Chemical Titan Corporation, Merck KGaA, and Tonen General Sekiyu K.K.


Looking for a locksmith on manique 2645?
Contact us if you have a broken lock. Our locksmiths can provide you with a modification that will put your mind at rest in manique 2645.
Our Glaziers to manique 2645 rehabilitation your leads shutter within the hour following your arrive and assist you meet the most competitive answers to all your leads malfunctions of shutter to manique 2645. troubleshooting of roller shutter doors at manique 2645 Want an effective professional an expert specialist locksmith shop and happens as soon as possible at dwelling for a rate not expensive? in manique 2645 dpp.pt and his entire team of Locksmiths to manique 2645 are available to help and intervene at apartment very as swiftly as possible for any hiccup in the field of Locksmithing to manique 2645.
We all work hard on a daily basis to pay for the possessions that are inside of our homes, and it can be difficult If you don't change a lock that has broken quickly then you could conceivably be putting your own flat at risk in manique 2645.
Replacing a broken lock is an easy task for any skilled insured certified locksmith If you need someone to put in install some modification locks on your property, give us a call today in manique 2645. dpp.pt as a consequence propose the commissioning market or replace of your column locks or closing cowhide anti_panique to manique 2645. There's never need to go to discerns worried about the security of your home You may not realise that a professional insured locksmith can put in place in position a replacement for a broken lock the very same day in manique 2645. dpp.pt is formed of at your pipeline mend for all your leads work in the field of Locksmithing to manique 2645.
Close door groom cowhide manique 2645 Do you have a broken lock? Don't leave your family and property at risk. We can change the lock quickly and easily in manique 2645. For your leads discounts in condition in emergency locksmith in manique 2645 we can easily arrive flat very before you know it and in time. Keys sometimes will proceed to vanishing acts, where they appear to break down. Locksmiths know how to handle these situations, and they will usually recommend that you alter the lock for your safety in manique 2645.
professional locksmith near my location in manique 2645. Car key replacement in manique 2645. I locked my keys in my car in manique 2645. specialist locksmith certified locksmith in manique 2645. Emergency car unlock service in manique 2645. Lock and key service in manique 2645. Local certified locksmith dc in manique 2645. certified registered professional locksmith in manique 2645. How to become a licensed specialist locksmith in manique 2645. Cheap emergency certified locksmith in manique 2645. specialist locksmith locked keys in car in manique 2645. Find locksmith nearby in manique 2645. 24 hour certified locksmith in manique 2645. Car key cutting in manique 2645. specialist locksmith charges in manique 2645. locksmith denver in manique 2645. Call professional locksmith in manique 2645. I need a locksmith in manique 2645. Key blanks in manique 2645. professional locksmith facebook in manique 2645. Commercial door locks in manique 2645.
High security locks in manique 2645. Industrial locksmith in manique 2645. professional locksmith near me in manique 2645. specialist locksmith dallas in manique 2645. Keyless lock in manique 2645. Duplicate residence keys in manique 2645. Car key transponder in manique 2645. Vehicle locksmith in manique 2645. Local specialist locksmith for car in manique 2645. specialist locksmith san francisco in manique 2645. Keysmith services in manique 2645. 24 hr specialist locksmith near me in manique 2645. Emergency lockout put right in manique 2645. Key fobs near me in manique 2645. Closest specialist professional locksmith to my location in manique 2645. specialist professional locksmith dc in manique 2645. specialist certified locksmith inspections in manique 2645. Auto key in manique 2645. How to get specialist certified locksmith certification in manique 2645. 24 hour specialist specialist locksmith near my location in manique 2645.
A specialist specialist locksmith near me in manique 2645. Cheap automotive certified locksmith in manique 2645. How much is a specialist locksmith in manique 2645. Local specialist professional locksmith services near me in manique 2645. 24 7 available specialist locksmith in manique 2645. Pop lock in manique 2645. specialist locksmith nj in manique 2645. Discount locksmith in manique 2645. American local professional locksmith in manique 2645. Auto key cutting in manique 2645. Auto specialist specialist locksmith rates in manique 2645. Car specialist locksmith okc in manique 2645. Emergency car key professional locksmith in manique 2645. 24 hour specialist professional locksmith milwaukee in manique 2645. specialist specialist locksmith for dwelling near me in manique 2645. Call a specialist locksmith in manique 2645. Locked out of car put right near me in manique 2645. Closest certified locksmith in manique 2645. Auto car key specialist locksmith in manique 2645.


Ham and Cheese Quiche couldn't be an easier meal to make and it tastes so good. I remember when I was a kid and my mom would make one and there was no way I was going to touch it! But now I love quiche and this one is as simple as it gets.
Beat Eggs then add milk, salt and pepper. Put cheese into pie crust, dump in milk and egg mixture.
Cover pie edges with foil. Bake for about 40 minutes on 400° or until a knife inserted in the center comes out clean. You can see this one got a little dark because I always worry about not cooking them long enough! But let it sit for 5-10 minutes and it will be perfect!
It's time to eat up! YUM!
I love quiche! Sometimes in the summer, I'll make it and pair it with a green salad. Thanks for sharing this yummy recipe with us at Foodie Fridays!


Next month's Caloundra Cup is on the cards for the shock Chairman's Handicap winner on Doomben 10,000 Day, the Stephen Lee-trained Anton En Avant scoring an upset at $151 odds in the Group 3.
Upset Chairman's Handicap winner Anton En Avant (pictured in September 2016) is onto the 2018 Caloundra Cup next month. Photo: Daniel Costello.
The eight-year-old son of Dubawi showed huge improvement in the Group 3 $125,000 Chairman's Handicap (2000m) after a lead-up 13th in the Listed Tails Stakes (1600m) at the Doomben track on April 21.
Enjoying his first win since October last year, the gallant old stayer posted his fourth win at the course from 21 starts on way to a shot at the Listed $175,000 Caloundra Cup (2400m) over the mile and a half at the Sunshine Coast on June 30.
Lee was full of post-race praise for his galloper who ducked back to the inside late on the home straight to run home ahead of the better fancied Lovani ($12) and Rising Red ($7) who ran second and third respectively.
"He's plain, he's small, he's exactly like me but he's got a lot of heart," an excited Lee said.
"I was fairly confident…this horse has just improved out of sight since moving to the [Gold] Coast on a bigger track.
"I was just trying to get some miles under his legs ahead of the Caloundra Cup cause he'll run 2600m.
Anton En Avant was ridden to victory by Matthew McGillivray who made it a double on 10,000 Day having also guided the Toby Edmonds-trained Havasay to victory in the first, the young hoop breaking a 62 day winning drought.
"We had a bit of luck with him today," McGillivray said of the dream ride he enjoyed on Anton En Avant, all the gaps opening up late for the eventual winner in the Chairman's Handicap.
"He was strong to the finish.
Hard luck story in the Chairman's Handicap was the Kim Waugh-trained favourite Goathland.
The last start ANZAC Cup (1800m) winner at Randwick on ANZAC Day got posted three and four wide throughout working very hard the entire run before eventually crossing second last.
The two placegetters in the Chairman's Handicap results however enjoyed dream runs up on the speed set by the Edmonds-trained Mr Epic who was revved up from out wide to go forward early.
Mr Epic led the field around from the Trent Busuttin & Natalie Young-trained Redwood four-year-old Rising Red, runner-up in last year's NZ Derby behind Gingernuts in March of 2017.
Eventual runner-up Lovani meanwhile travelled third throughout on the outside, the Brad Widdup-trained Lonhro mare coming off a Hawkesbury Cup fifth before her second to Anton En Avant.
To back Anton En Avant next race and access the best Caloundra Cup 2018 odds next month head to Ladbrokes.com.au.